Literature DB >> 27941501

Isoflurane Sedation on the ICU in Cardiac Arrest Patients Treated With Targeted Temperature Management: An Observational Propensity-Matched Study.

Alexander Krannich1, Christoph Leithner, Martin Engels, Jens Nee, Victor Petzinka, Tim Schröder, Achim Jörres, Jan Kruse, Christian Storm.   

Abstract

OBJECTIVE: Targeted temperature management after cardiac arrest requires deep sedation to prevent shivering and discomfort. Compared to IV sedation, volatile sedation has a shorter half-life and thus may allow more rapid extubation and neurologic assessment.
DESIGN: Observational analysis of clinical data.
SETTING: University hospital, medical ICU. PATIENTS: Four hundred thirty-two cardiac arrest survivors underwent targeted temperature management; of those, 110 were treated with volatile sedation using an anesthetic conserving device and isoflurane, and 322 received standard IV sedation. INTERVENTION: No intervention. MEASUREMENT AND MAIN
RESULTS: A matched pairs analysis revealed that time on ventilator (difference of median, 98.5 hr; p = 0.003) and length of ICU stay (difference of median, 4.5 d; p = 0.006) were significantly shorter in patients sedated with isoflurane when compared with IV sedation although no differences in neurologic outcome (45% of patients with cerebral performance category 1-2 in both groups) were observed. Significant hypercapnia occurred more frequently during anesthetic conserving device use (6.4% vs 0%; p = 0.021).
CONCLUSIONS: Volatile sedation is feasible in cardiac arrest survivors. Prospective controlled studies are necessary to confirm the beneficial effects on duration of ventilation and length of ICU stay observed in our study. Our data argue against a major effect on neurologic outcome. Close monitoring of PaCO2 is necessary during sedation via anesthetic conserving device.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27941501     DOI: 10.1097/CCM.0000000000002185

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care.

Authors:  Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2021-03-25       Impact factor: 17.440

2.  Isoflurane Sedation in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation Treatment for Cardiogenic Shock-An Observational Propensity-Matched Study.

Authors:  Clemens Scherer; Danny Kupka; Thomas J Stocker; Dominik Joskowiak; Hanna Scheuplein; Carmen Maria Schönegger; Frank Born; Christopher Stremmel; Enzo Lüsebrink; Konstantin Stark; Mathias Orban; Tobias Petzold; Sven Peterss; Jörg Hausleiter; Christian Hagl; Steffen Massberg; Martin Orban
Journal:  Crit Care Explor       Date:  2020-03-24

3.  Inased (inhaled sedation in ICU) trial protocol: a multicentre randomised open-label trial.

Authors:  Pierre Bailly; Pierre-Yves Egreteau; Stephan Ehrmann; Arnaud W Thille; Christophe Guitton; Guillaume Grillet; Florian Reizine; Olivier Huet; S Jaber; Emmanuel Nowak; Erwan L'her
Journal:  BMJ Open       Date:  2021-02-19       Impact factor: 2.692

4.  Sevoflurane Dampens Acute Pulmonary Inflammation via the Adenosine Receptor A2B and Heme Oxygenase-1.

Authors:  Kristian-Christos Ngamsri; Anika Fuhr; Katharina Schindler; Mariana Simelitidis; Michelle Hagen; Yi Zhang; Jutta Gamper-Tsigaras; Franziska M Konrad
Journal:  Cells       Date:  2022-03-24       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.